Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.F., Testori, A., Grob, J.J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller Jr., W.H., Gascon, P., Lotem, M., Har-Mankaya, K., Ibrahim, R., Francis, S., Chen, T.T., Humphrey, R., Hoos, A. and Wolchok, J.D. (2011) Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 364, 2517-2526.
http://dx.doi.org/10.1056/NEJMoa1104621

has been cited by the following article:

• TITLE: Is Use of Radiation Hormesis the Missing Link to a Better Cancer Treatment?

  AUTHORS: Paul A. Oakley

  KEYWORDS: Cancer, Radiation Hormesis, Abscopal Effect, Therapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.7, July 16, 2015

  ABSTRACT: Radiation hormesis is a concept that pervades radiobiological exposures; low doses enhance immune response, while higher doses inhibit immune response. Low-dose Total-Body Irradiation (TBI) therapy offers radiation treatment to cancer patients using the concepts of radiation hormesis and show very good success rates. This phenomenon has been reported elsewhere as the “abscopal effect” and considering the marginal success rates of other treatment agents, like the immunotherapy drug Ipilimumab, TBI therapy may prove to be the missing link to a better cancer treatment.